Loading...
Market
Dupixent becomes top-selling Sanofi drug by mid-2025?
2
Resolution / Starting Odds
Yes • 50%
No • 50%
Sanofi's official sales data
Story
Sanofi and Regeneron’s Dupixent Approved for COPD, 'Smoker's Lungs,' in EU
Jul 3, 2024, 05:15 AM
Sanofi and its partner Regeneron have received European Union approval on Wednesday for the expanded use of their Dupixent injection to treat patients with chronic obstructive pulmonary disease (COPD). This marks the first-ever targeted therapy for COPD, also referred to as 'smoker's lungs,' approved in the EU. Notably, the EU's approval process for Dupixent was faster than that of the United States, highlighting a rare instance of expedited clearance. The approval is expected to create a new growth avenue for the blockbuster drug.
View original story
Similar markets
Less than 10% • 25%
10% to 20% • 25%
20% to 30% • 25%
More than 30% • 25%
Novo Nordisk • 25%
Eli Lilly • 25%
Pfizer • 25%
Other • 25%
Wegovy • 25%
Zepbound • 25%
Ozempic • 25%
Other • 25%
Less than $500 million • 25%
$500 million to $1 billion • 25%
$1 billion to $1.5 billion • 25%
More than $1.5 billion • 25%
